Table 1.
Characteristics of Participating Centers and CAR Products
| Characteristic | Centers, n(%) (n=11) |
|---|---|
| Total Hospital Beds | |
| 1-50 | 1 (9) |
| 50-100 | 1 (9) |
| 100-250 | 2 (18) |
| 250-500 | 1 (9) |
| >500 | 6 (55) |
| Total Medical ICU Beds | |
| 1-10 | 1 (9) |
| 11-20 | 4 (36) |
| 21-30 | 1 (9) |
| > 30 | 5 (46) |
| Type of ICU | |
| Exclusively oncological | 8 (73) |
| Mixed | 3 (27) |
| CAR Products Used | |
| Commercial | 9 (82) |
| Clinical trial protocols | 9 (82) |
| Institutional products | 4 (36) |
| Toxicity Grading Guidelines Utilized | |
| ASTCT | 10 (91) |
| Other | 1 (9) |
| Treatment Guidelines Utilized | |
| Institutional | 5 (46) |
| Neelapu 20179 | 3 (27) |
| Lee 201413 | 2 (18) |
| Specific to the clinical trial protocol | 1 (9) |
| CAR Infusions to Date* | |
| Commercial products | |
| 0-50 | 6 (55) |
| 51-100 | 3 (27) |
| >100 | 2 (18) |
| Non-commercial products | |
| 0-50 | 7 (64) |
| 51-100 | 0 (0) |
| >100 | 4 (36) |
| Infection Prophylaxis Guidelines for CAR patients | 7 (64) |
*
Patients treated to date as of distribution of survey (June 2019)
ASTCT - American Society for Transplantation and Cellular Therapy; CAR - chimeric antigen receptor; ICU - intensive care unit;